Possible Involvement of Cationic-Drug Sensitive Transport Systems in the Blood-To-Brain Influx and Brain-To-Blood Efflux of Amantadine Across the Blood-Brain Barrier

The purpose of this study was to characterize the brain-to-blood efflux transport of amantadine across the blood-brain barrier (BBB). The apparent in vivo efflux rate constant for [H-3]amantadine from the rat brain (k(eff)) was found to be 1.53x10(-2)min(-1) after intracerebral microinjection using the brain efflux index method. The efflux of [H-3]amantadine was inhibited by 1-methyl-4-phenylpyridinium (MPP+), a cationic neurotoxin, suggesting that amantadine transport from the brain to the blood across the BBB potentially involves the rat plasma membrane monoamine transporter (rPMAT). On the other hand, other selected substrates for organic cation transporters (OCTs) and organic anion transporters (OATs), as well as inhibitors of P-glycoprotein (P-gp), did not affect the efflux transport of [H-3]amantadine. In addition, in vitro studies using an immortalized rat brain endothelial cell line (GPNT) showed that the uptake and retention of [H-3]amantadine by the cells was not changed by the addition of cyclosporin, which is an inhibitor of P-gp. However, cyclosporin affected the uptake and retention of rhodamine123. Finally, the initial brain uptake of [H-3]amantadine was determined using an in situ mouse brain perfusion technique. Notably, the brain uptake clearance for [H-3]amantadine was significantly decreased with the co-perfusion of quinidine or verapamil, which are cationic P-gp inhibitors, while MPP+ did not have a significant effect. It is thus concluded that while P-gp is not involved, it is possible that rPMAT and the cationic drug-sensitive transport system participate in the brain-to-blood efflux and the blood-to-brain influx of amantadine across the BBB, respectively. Copyright (c) 2014 John Wiley & Sons, Ltd.